{
  "docId": "019de073-a45e-764e-97a1-b4793295a3f1",
  "docSlug": "90578b12d3108983c23425e7ddd95d83",
  "documentTitle": "ATAI | Investor Presentation Deck | 41 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 41,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "before_after",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a45e-764e-97a1-b4793295a3f1/28",
  "deckHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1",
  "deckJsonHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1.json",
  "deckAnchorHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Non Inferiority Test",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61ea9915-a8aa-4564-bdde-e5aa5fd250d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Etifoxine works as rapidly as lorazepam, with etifoxine continuing its effects beyond treatment, while lorazepam shows rebound",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "636c0770-02ad-44d8-93f9-4ecc87b64681",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "list",
      "text": "Etifoxine has a strong safety record: a review of over 14m prescriptions between 2000 and 2012 in France found no cases of abuse, misuse or dependence",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9017a5bf-9255-4ef3-9310-0152553aa5b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Etifoxine has been approved for anxiety disorder since 1979 with 14m+ prescriptions in France",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b98d03d5-f863-4736-b324-fc67c026bc6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: HAM-A = Hamilton Anxiety Rating Scale. 1. Cottin et al., 'Safety profile of etifoxine: A French pharmacovigilance survey' (2016). 2. Nguyen et al., 'Efficacy of etifoxine compared to lorazepam monotherapy' (2006)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16e4d983-02ab-43a0-938d-760a2fd6162a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "GRX-917 has the potential for benzodiazepine-like efficacy with improved safety and tolerability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aed7c453-5052-4d36-9e81-021c41c6fb78",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "886678ed-7ffb-4ecb-8ab2-a52d3953c820",
      "evidence": "The slide compares the effects of Etifoxine and Lorazepam on anxiety disorder, showing a before-after comparison.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "b6630ed2-aa02-455f-93ec-2466ac237893",
      "evidence": "Compares current standard (Lorazepam) with proposed solution (Etifoxine/GRX-917) efficacy and safety.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 41,
      "from": 6,
      "beatId": "54d980bb-d331-41ca-8841-b0eb7beb049c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides a solution by showcasing ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 40,
      "from": 10,
      "beatId": "4c06d6d1-b3e1-4c1e-bceb-806b8f57a880",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides evidence and proof of the effectiveness of ATAI Life Sciences' treatments through various studies and data.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5cd92045-52c0-4b53-b15d-4dd6b345ff72",
      "evidence": "The presentation showcases ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 1,
      "objective": "How can we effectively treat mental health disorders?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}